RGBPP Company Profile and Key Details

The stock is currently mid-range between its 52-week high and low $0.00 and $0.10. With a market capitalization of about $113.55 thousand, Regen BioPharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.24). Key stats such as the average daily volume over the past year has been around 204.47 thousand shares, volume is running light vs its 52-week average. Headquartered in La Mesa, CA, Regen BioPharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Raymond Koos, the company employs approximately 1 people and listed since April 20, 2016. Regen BioPharma, Inc. is dedicated to advancing regenerative medicine solutions across the United States.

Average 10-day trading volume of 371.95 thousand shares is significantly above the 3-month average of 220.01 thousand, indicating heightened recent market interest.

Regen BioPharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.94. This means the shares are trading below this model’s fair value.

Valuation shows Regen BioPharma, Inc. trading at a premium to the broader market with a P/E of -0.01.

Our AI price prediction model suggests that Regen BioPharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Regen BioPharma, Inc. trades at a P/E ratio of -0.01, slightly below the S&P 500 average, with a price-to-sales ratio of 0.01 and a price-to-book ratio of -0.01 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.01, also above market averages.